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ABSTRACT
In Chronic Myeloid Leukemia 80% of patients present alternative splice variants 
involving BCR exons 1, 13 or 14 and ABL exon 4, with a consequent impairment 
in the reading frame of the ABL gene. Therefore BCR/ABL fusion proteins (BCR/
ABL-OOF) are characterized by an in-frame BCR portion followed by an amino acids 
sequence arising from the out of frame (OOF) reading of the ABL gene. The product 
of this new transcript contains the characteristic BCR domains while lacking the 
COOH-terminal Rho GTPase GAP domain. The present work aims to characterize the 
protein functionality in terms of cytoskeleton (re-)modelling, adhesion and activation 
of canonical oncogenic signalling pathways. Here, we show that BCR/ABL-OOF has a 
peculiar endosomal localization which affects EGF receptor activation and turnover. 
Moreover, we demonstrate that BCR/ABL-OOF expression leads to aberrant cellular 
adhesion due to the activation of Rac GTPase, increase in cellular proliferation, 
migration and survival. When overexpressed in a BCR/ABL positive cell line, BCR/
ABL-OOF induces hyperactivation of Rac signaling axis offering a therapeutic 
window for Rac-targeted therapy. Our data support a critical role of BCR/ABL-OOF in 
leukemogenesis and identify a subset of patients that may benefit from Rac-targeted 
therapies.
INTRODUCTION
Chronic Myelogenous Leukemia (CML) is 
a myeloproliferative disorder characterized by the 
Philadelphia chromosome [1, 2], which originates from 
a reciprocal translocation involving the BCR gene on 
chromosome 22 and c-ABL on chromosome 9. The BCR/
ABL protein product is a constitutively active oncogene 
(p210 BCR/ABL) which is necessary and sufficient for 
CML development [3, 4, 5]. Imatinib (IM) is the frontline 
therapy for CML patients, achieving an high rate of Major 
Molecular Response (MMR; defined as 3-log reduction 
in BCR/ABL transcript level from a standardized baseline 
value) and Complete Molecular Response (CMR; defined 
as at least 4-log reduction corresponding to undetectable 
BCR/ABL transcript by real-time reverse transcription 
polymerase chain reaction) [6, 7] which might represent 
an ‘operational cure’ as well as a pre-requisite for IM 
discontinuation [8]. 
Still, there are a number of patients with p210 BCR/
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ABL carrying kinase mutations that may contribute to 
IM resistance. The second generation kinase inhibitors 
Dasatinib and Nilotinib have been developed and are 
currently used in IM non-responder CML patients [9, 10], 
even though the chance to select a clone resistant to both 
drugs is still high [11].
In order to seek alternative pharmacological 
approaches (i.e. druggable molecules), we focused on the 
extra components downstream of BCR/ABL which may 
represent additional molecular targets for (IM) resistant 
patients.
As reported in our previous reports [12], we 
identified a new alternative splice variant derived from 
BCR/ABL transcript in which the fusion involved the 
exons 1-13 or 14 of BCR and exon 4 (in spite of exon 2) 
of c-ABL. This alternative splicing induces a change in the 
reading frame of ABL portion generating an early STOP 
codon in the middle of c-ABL exon 5. The latter results 
in the production of a fusion protein defined by an initial 
(and correctly read) BCR portion attached to a sequence of 
amino acids arising from the out of frame (OOF), leading 
to the c-ABL exon 4 and 5 gene sequence.
It is worth mentioning that this protein is largely 
studied for its attractive immunological function [13, 
14, 15]. In order to investigate a possible Bcr/Abl-OOF 
oncogenic role we focused our attention on its peculiar 
structure generated as a consequence of the alternative 
splicing. The BCR/ABL-OOF product gene is a 120 kDa 
protein which lacks the BCR COOH-terminal Rac GAP 
domain [16], which is fundamental to balance cytoskeleton 
dynamics trough the regulation of the Rho-like GTPases 
activity [17, 18].
Rho GTPases have been previously described for 
their important roles in Bcr/Abl-mediated transformation 
as downstream components, with a specific involvement 
for Rac GTPases [19, 20, 21]. Interestingly, in a leukemia 
murine model, the deficiency of Rac1 and Rac2 leads 
to a significant attenuation of the malignant phenotype. 
Furthermore a Rac-specific small molecule inhibitor 
(NSC23766) was able to reduce the leukemic burden in 
vivo in NOD/SCID mice transplanted with chronic-phase 
CML CD34+ cells [22]. 
Thus, to determine the role of the BCR/ABL-
OOF, we analyzed the effects of the protein in terms of 
cytoskeleton (re-)modelling, adhesion, activation of Rho 
GTPases and oncogenic pathways. Altogether the current 
study identifies a new role for the Bcr/Abl transcript 
variant protein product and thus it may suggest its new 
potential as therapeutic target in CML. 
RESULTS
BCR/ABL-OOF localizes predominantly in 
microsomes of HeLa cells
To study the proper BCR/ABL-OOF protein 
localization, we used the expression vector pCDNA 3.1 
BCR/ABL-OOF, generated by our laboratory as previously 
described [13].
Hela cells expressing BCR/ABL-OOF protein 
were subjected to immunofluorescence and western blot 
assay 48 h post-transfection. The immunofluorescence 
assay revealed that BCR/ABL-OOF presents a peculiar 
vesicular and cytoplasmatic localization (Figure 1A). The 
same assay performed with PIPES 0,1% saponin showed 
that BCR/ABL-OOF maintained a strong signal inside the 
vesicular compartment. Altogether these results supported 
our hypothesis that BCR/ABL-OOF is linked to the 
cytoskeletal structure (Figure 1B).
HeLa BCR/ABL-OOF expressing cells were lysed 
with a previous described protocol [23] which allow to 
preserve different subcellular compartments. We focused 
on the microsomal fraction containing a mixture of many 
organelles, such as Golgi, ER and intracellular vesicles. 
As shown in Figure 1C, BCR/ABL-OOF is expressed in 
large amount in the vesicular compartment, confirming the 
results obtained by immunofluorescence.
BCR/ABL-OOF is localized in endosomal vesicles 
and interacts with p160 BCR
To investigate which type of vesicles were 
associated to BCR/ABL-OOF, immunofluorescence 
analysis of BCR/ABL-OOF and of a known marker 
of early endosomal vesicles EEA1 was performed 
after PIPES 0,1% saponin treatment. BCR/ABL-OOF 
protein exhibited a similar staining pattern localization 
in endosomal vesicles where EEA1 is physiologically 
located (Figure 1D). The same result was confirmed 
on cells co-trasfected with BCR/ABL-OOF and p160 
BCR, which is localized in the endosomal compartment 
[24, 25]. It is well known that BCR is a component of 
mammalian ESCRT complexes and it plays an important 
role in proteins sorting during endosomal trafficking by 
interaction with TSG101. Because the region involved in 
this interaction is lost in BCR/ABL-OOF, we investigated 
whether a direct interaction between p160 BCR and Bcr/
Abl-OOF could be responsible for its localization. Indeed, 
Immunoprecipitation analysis show that BCR/ABL-
OOF and p160 BCR co-immunoprecipitate (Figure 1E). 
Immunofluorescence analysis showed a co-localization of 
BCR and BCR/ABL-OOF in endosomal vescicles (Figure 
1F), thus confirming previous results. 
Next, given the importance of endosomial p160 
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Figure 1: BCR/ABL-OOF localized predominantly in endosomes of HeLa cells where it interacts with p160 BCR. 
Immunofluorescence assay using Rabbit anti OOF policlonal antibody on BCR/ABL-OOF HeLa transfected cells before (A) and after (B) 
the treatment with PIPES and 0,1% Saponin C) Western blot analysis of cytosolic and microsomal fractions of BCR/ABL-OOF transfected 
HeLa cells. Protein extracts were examined for expression of Bcr/Abl-OOF by immunoblotting with polyclonal Rabbit anti OOF. Actin 
and GM130 expression, were detected, using specific antibodies, as markers respectively of the cytosolic and microsomal compartment. 
D) Immunofluorescence with antibody anti EEA1 (red signal) and BCR/ABL-OOF (green signal) on Hela cells trasfected with BCR/ABL-
OOF.E) Immunoprecipitation of protein extracts from HeLa cells co-expressing exogenous BCR/ABL-OOF and p160 BCR using rabbit 
anti-OOF antibody followed by immunoblotting with anti Bcr. F) Immunofluorescence with antibody anti BCR (red signal) and BCR/
ABL-OOF (green signal) on Hela cells cotrasfected with pcDNA BCR/ABL-OOF and p160 BCR. G) Analysis of EGF-receptor activation 
in BCR/ABL-OOF Hela cells in term of phosphorylation by western blot after EGF ligand stimulation (50 ng/ml at different time point: 0, 
30’, 1h, 2h and 4h). H) Localization of BCR/ABL-OOF by immunofluorescence after EGF ligand stimulation (50 ng/ml at different time 
point: 0, 5’, 10’, 30’ and 60’ . Figure 1G is representative of 30’ of EGF stimulation).
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BCR in the physiological turnover and recycling of EGF 
receptor [24] we decide to investigate whether BCR/
ABL-OOF was also involved. In order to evaluate this 
possibility, we analyzed EGF receptor activation levels 
in the presence of BCR/ABL-OOF protein upon EGF 
ligand stimuli. By western blot analysis, we observed 
an increased in phosphorylation levels of EGF receptor 
compared to cells transfected with empty vector (Figure 
1G). This result is also supported by immunofluorescence 
analysis where there is an increase in the submembrane 
localization of BCR/ABL-OOF at 30 minutes of EGF 
ligand stimulation (Figure 1H). This result suggests that 
BCR/ABL-OOF may cooperate in endosome-mediated 
receptor internalization.
BCR/ABL-OOF expression leads to Rac activation
To understand whether the absence of GAP domain 
as a consequence of BCR/ABL alternative splicing could 
confer some peculiarity to BCR/ABL-OOF protein, we 
investigated the status of Rho family proteins in HeLa 
BCR/ABL-OOF expressing cells in comparison to cells 
transfected with the active forms of Rho or Rac . 
Since cell adhesion can be modified by the 
activation pattern of Rho-like GTPases through an inside-
out mechanism we performed an adhesion assay as 
described in materials and methods. HeLa cells expressing 
BCR/ABL-OOF showed significant modifications in 
spreading to fibronectin respect to control cells transfected 
with empty vector. Their morphological pattern was quite 
similar to that of HeLa cells transfected with the active 
form of Rac, while differing from those transfected with 
the active form of Rho (Figure 2 A, 2B, 2C, 2D). 
We next decided to perform immunofluorescence 
analysis of HeLa BCR/ABL-OOF expressing cells by 
using a dual staining with anti-OOF and anti-Rho or 
anti-Rac antibodies respectively. We observed that while 
endogenous Rho remained totally diffused inside the cell, 
endogenous Rac had a peculiar distribution under the cell 
membrane which corresponded to Rho GTPases activated 
form localization [26] (Figure 2E). These results suggest 
that Rac activation may be responsible for mediating 
BCR/ABL-OOF cell morphology changes during cell 
adhesion to fibronectin. 
The activation of Rac was also confirmed by a 
pulldown assay using Rac GTPase binding domain as 
GST fusion protein bound to glutathione-sepharose beads 
(GST PAK-CD). This fusion protein was able to trap a 
significant proportion of GTP-bound Rac form in lysates 
coming from BCR/ABL-OOF HeLa cells in the same 
manner as cells transfected with the active form of Rac 
(Rac V12) thus supporting the presence of Rac in the 
active form (Figure 2F).
BCR/ABL-OOF induces cellular proliferation, 
migration and survival 
On the basis of the latter results, we were interested 
to investigate a possible involvement of BCR/ABL-
OOF in the activation of canonical oncogenic signalling 
pathways. For this purpose, HeLa cells were trasfected 
with pcDNA BCR/ABL-OOF and 48 h post-transfection 
cells were selected with G418 for 14 days to enrich 
the amount of positively transfected cells. Apoptosis 
assay illustrates that BCR/ABL-OOF cells have a lower 
apoptotic rate than transfected cells with empty pcDNA 
(normal control), with 62% reduction of apoptosis 
(p=0,002) (Figure 3A). Proliferation assay was performed 
through evaluation of 3H incorporated in proliferating 
cells.These results suggest that BCR/ABL-OOF cells 
proliferate more compared with pcDNA control cells 
(2 fold of induction, (Figure 3B). In addition, migration 
assay performed by using 20% serum as stimuli shown 
an increased capacity of BCR/ABL-OOF cells to migrate 
compared to control cells (Figure 3C).
In order to confirm the importance of Rac activation 
in the behaviour of BCR/ABL-OOF positive cells we 
decided to treat these cells with a specific Rac inhibitor, 
NSC23766. [21]. In accordance with previous results, we 
found both the proliferation and migration of BCR/ABL-
OOF HeLa expressing cells strongly reduced. In addition, 
we observed an increased in apoptosis. Altogether these 
results suggest that Rac signalling could be a major 
component in BCR/ABL-OOF-mediate activity (Figure 
3B and 3C). 
In order to evaluate whether BCR/ABL-OOF 
expression could affect canonical oncogenic signalling 
pathways, we next analysed by western blot possible 
differences in Akt, Cyclin D and p38 expression. (Figure 
3D, 3E and 3F).
Interestingly, we found that basal phospho-Akt 
(Ser473) levels were already significantly increased in 
cells transfected with BCR/ABL-OOF, with the highest 
expression at 30 minutes of EGF stimulation (p< 0.001) 
(Figure 3D); the latter result may correlate with the basal 
reduction of apoptosis observed in these cells. 
Cyclin D was analysed as positive activator of DNA 
synthesis and, as consequence, of cells proliferation; 
our data demonstrated an increased cyclin D level in 
BCR/ABL-OOF cells both in basal condition and under 
EGF stimulation, confirming the results obtained in the 
proliferation assay (Figure 3E).
Finally, the stress-activated p38 mitogen-activated 
protein (MAP) kinases was also analysed due to its strong 
Rac regulation; it is well described that constitutively 
active forms of Rac leads to activation of p38 by the 
action of p21-activated Kinase 1 (Pak1) as mediator [27]. 
Interestingly, under basal conditions, p38 activation is 
already high in cells transfected with pcDNA BCR/ABL-
OOF even in absence of growth factor stimuli, confirming 
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Figure 2: Rac is activated in cells transfected with pcDNA BCR/ABL-OOF. HeLa cells were respectively transfected with 
different constructs, pcDNA Bcr/Abl-OOF (A), pEXV-mycRhoV1 (B), pEXV-mycRacV12 (C) and empty pcDNA (D). Immunofluorescence 
was performed after one hour adhesion on fibronectin coated coverslips by using the specific antibody rabbit anti-OOF (A), mouse anti-Rho 
(B) and mouse anti-Rac (C) subsequently evidenced by FITC secondary antibody. Red phalloidin was used to take evidence of cytoskeleton 
structure. E) cells transfected with pcDNA BCR/ABL-OOF were used for immunofluorescence assay performed with rabbit anti-OOF (green 
signal) and respectively with mouse anti-Rac or mouse anti-Rho (red signal) after one hour adhesion on fibronectin coated coverslips. Rac 
partial membrane or submembrane localization suggested its activation form. F) Lysates derived from HeLa cells transfected with empty 
pcDNA, BCR/ABL-OOF or pEXV-mycRacV12 were incubated with GST PAK-CD for the pull down assay and subsequently processed by 
western blot.. 15 µg of total lysate was shown as control of equal quantity of lysate in the different fractions.
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Figure 3: BCR/ABL-OOF induces cellular proliferation, migration and survival. A) Apoptosis rate on HeLa BCR/ABL-
OOF or empty vector was analyzed by flow cytometry analysis with FITC Annexin V antibody and PI Propidium cell staining. B) 1 μCi/
ml of timidine (3H) was incubated for 24 hours during proliferation in cells transfected with empty vector or with BCR/ABL-OOF in basal 
condition or after incubation with Rac inhibitor NSC23766. β counter measure is expressed as cpm (counts per minute). C) Migration 
assay was performed with 1x104 cells by using 8µm pore size transwell. Cells migrated after 22 hours were counted by stained with May 
Grunwald Giemsa staining. D) Forty eight hours after transfection, HeLa cells were starved for 12 hours and stimulated with EGF ligand 
(50ng/ml) for different time point (0, 30, 120 minutes). Lysates were collected and they were examined by western blot for expression of 
pAKT (D), Cyclin D (E) and pp38 (F). Akt, GAPDH and p38 were used as loading control. The quantification was performed by ImageJ 
program.
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Figure 4: BCR/ABL-OOF can cooperate with BCR/ABL oncogenicity. A) RTQ-PCR assay and Western blot showing BCR/
ABL-OOF transcript and protein levels in BV173 Ph+ cell line transfected respectively with empty pcDNA and pcDNA BCR/ABLOOF 
B) Immunofluorescence assay performed on BV173 cells line transfected with pcDNA BCR/ABL-OOF using rabbit anti-OOF (green 
signal) and respectively mouse anti-Rac or mouse anti-Rho (red signal) antibodies after twenty-four hour of adhesion on fibronectin coated 
coverslips. C) Proliferation assay and D) migration assay performed on BV173 cell line transfected respectively with empty pcDNA and 
pcDNA BCR/ABL-OOF. E) Apoptosis assay on BV173 BCR/ABL-OOF positive after incubation with Rac inhibitor F) RTQ-PCR assay 
showing copies number of BCR/ABL-OOF transcript in CD34+ cell fraction coming from the bone marrow of 7 CML patients at diagnosis 
G) Representative analysis of the copies number of BCR/ABL-OOF transcript after three months of Imatinib treatment.
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the involvement of Rac activity as a result of BCR/ABL-
OOF protein expression in this cells (Figure 3F). 
Altogether these results suggest BCR/ABL-OOF as 
an important player during cell proliferation, survival and 
apoptosis in chronic myeloid leukaemia.
BCR/ABL-OOF can cooperate with BCR/ABL 
oncogenicity
As we have previously reported, BCR/ABL-OOF is 
an aberrant transcript that coexists with full length BCR-
ABL transcript [12]. We therefore sought to investigate 
whether BCR/ABL-OOF and BCR/ABL could synergize 
in leukemia cells. To this aim, we transfected BCR/
ABL-OOF in BV173 Ph+, hematopoietic cells which are 
characterized by a very low expression of BCR/ABL-
OOF protein. After confirming post-transfection BCR/
ABL-OOF expression levels by western blot and mRNA 
analysis (Figure 4A) Rac GTPase activity was evaluated 
upon fibronectin cell adhesion (Figure 4B). Under this 
condition we observed a strong Rac GTPase activation 
in BV173 BCR/ABL-OOF positive cell line meanwhile 
endogenous Rho pathway seemed to be not activated. A 
strong significant increased in cell proliferation (p=0,008) 
and migration (p=0,02) were observed in BCR/ABL-
OOF positive samples (Figure 4C and 4D). Interestingly, 
BV173 BCR/ABL-OOF cells are more sensitive to Rac 
inhibition, confirming the Rac pathway addiction in BCR/
ABL-OOF cells (Figure 4E). Given the high levels of Rac 
GTPases in CD34+ of CML patients and its importance 
as a key stimulator of ROS production [28] we decided 
to analyse by RT-Q-PCR the copy number of BCR/ABL-
OOF transcript on CD34+ positive cells derived from the 
bone marrow of 7 CML patients. We observed a trend to 
increased mRNA BCR/ABL-OOF transcript expression 
compared to the CD34- fraction (Figure 4F), confirming 
the importance of BCR/ABL-OOF in the activation of the 
Rac pathway, especially in the more primitive leukemic 
compartment where it is highly expressed.
In order to find a correlation with the in vitro results, 
we next analyzed the expression levels of BCR/ABL-OOF 
in 16 patients after 3 months of imatinib treatment. In three 
patients, our analysis showed a slow reduction of BCR/
ABL-OOF transcript levels after three months of imatinib 
therapy. Interestingly, these patients display a worst 
response to Imatinb treatment (Figure 4G). These analyses 
raised the possibility that BCR/ABL-OOF cooperates 
with the oncogenic BCR/ABL pathway, suggesting a new 
attractive alternative to treat patients with a suboptimal 
response.
DISCUSSION
Alternative splicing (AS) is an essential biological 
process which drives proteome diversity. Besides AS 
role in many physiological processes [29], it represents 
an intriguing player also in cancer pathogenesis through 
a variety of mechanisms. Foremost, AS itself may be 
the result of mutations in genes that are involved in the 
regulation of the spliceosome, leading to the aberrant 
expression of several genes [30]. More recently, even in 
the absence of spliceosome gene mutations, the alternative 
splicing of specific genes has also been reported to bring 
important biological consequences. In this context, AS has 
been previously postulated to have potential therapeutic 
implications [30].
For instance, our previous results have shown 
that BCR/ABL alternative splicing isoforms lead to the 
expression of aberrant proteins [12]. Importantly, these 
proteins display immunological properties, thus offering 
a therapeutic window [12].
Here, we demonstrate an additional role for BCR/
ABL alternative splicing isoforms. In particular, we show 
that alternative proteins may have a potential role during 
tumorigenesis. We provide evidences demonstrating 
that BCR/ABL-OOF protein is able to increase cellular 
proliferation and migration and to inhibit apoptosis. 
Although tyrosine-kinase activity of BCR/ABL is essential 
for CML pathogenesis, additional BCR/ABL functions 
along with hematopoietic stem/progenitor cells and 
tumour microenvironment biology are likely to contribute 
to the disease development and maintenance. 
It is well described the p210 capability to induce an 
altered cell adhesion [31]; our data indeed demonstrate 
that BCR/ABL-OOF seemed to have an analog role and 
we hypothesizes that it may cooperate with BCR/ABL in 
massive cytoskeleton reorganization processes.
Herein we clearly demonstrate the ability of 
BCR/ABL-OOF to activate Rac. In particular, higher 
BCR/ABL-OOF expression levels were found in most 
undifferentiated hematopoietic CD34+ cells compared 
to CD34-cell population and indicate Rac as a new 
therapeutical target to block in order to inhibit leukemia 
stem cells.
Final point is the peculiar localization of Bcr/Abl-
OOF. This event may help Bcr/Abl-OOF to exert its GEF 
activity on the Rho GTPases, which function in the control 
of vesicular trafficking is well known [32, 33]. Moreover 
it could be implicated on the EGF receptor turnover, a 
process deregulated in many solid tumors [34]. Recent 
research showed the ability of an insect extracts (E. 
sinensis Walker) to inhibit the proliferation of leukemia 
K562 by inhibiting EGF secreting and blocking the EGFR 
signaling pathway, suggesting a relevance of EGFR in 
human hematological diseases [35]. Another study [36]
showed the EGF receptor ability to induce activation 
of non-canonical MAPK (p38, MEK/ERK) and PI3K 
pathways [37]. For these reasons targeting EGF and its 
direct activators could be a valuable alternative to inhibit 
tumor progression.
These interesting results will be prospectively tested 
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in patient cells (i.e. ex vivo) in order to confirm all the 
evidence obtained in in vitro cell line model. The fact that 
patients with slow reduction of both BCR/ABL and BCR/
ABL-OOF shown a suboptimal response could lead us 
to the conclusion that the lack of GAP domain in BCR/
ABL-OOF could induce an increased of persistence of 
Rac activation and increase cell tumorigenesis. 
All together our data suggest that BCR/ABL-OOF 
is actively involved in the BCR/ABL signalling due to 
its specific oncogenic properties and it could provide 
additional targets for developing new drugs in order to 
eradicate CML stem cells. This speculation could have 
tremendous consequences from the therapeutic standpoint. 
Although additional investigations are necessary to 
better establish the overall impact of AS transcript in 
cancer pathogenesis, this work suggests that the cancer 
trascriptional machinery could act favoring the expression 
of many oncogenic isoforms which could be responsible 
of different sensitivity to therapeutic agents (i.e. TKI) [38]. 
MATERIALS AND METHODS
Plasmids
The pcDNA 3.1 BCR/ABL-OOF construction 
was previously described by Casnici et al. 2011 [14]. 
The PAULO-BCR p160 was kindly provided by M. 
Ruthardt (16); the pcDNA 3.1 BCR/ABL was generated 
by subcloning the 7kb EcoRI-BCR/ABL cDNA contained 
in pGD210, kindly provided by GQ. Daley [39], in 
pcDNA 3.1. pGEX PAK-CD, pEXV-mycRhoV1, pEXV-
mycRacV12 were kindly provided by P. Defilippi (MBC, 
University of Turin).
Human CML samples
16 Primary CML bone marrow samples were 
collected at diagnosis after informed consent. CD34 
positive cells were isolated from 7 bone marrow aspirate 
accordingly to the Miltenyi Biotec protocol for CD34 
purification (Miltenyi Biotec, #130-094-531). The amount 
of the alternative transcripts in patients RNA at diagnosis 
and after three months of therapy was evaluated as 
previously described [12].
Cell culture, transfection assay and pharmacological 
treatments: HeLa cells line was maintained in RPMI 1640 
(Euroclone) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS, Sigma Aldrich) and 2mM glutamine 
(Euroclone) at 37°C in a 5% CO2 humified atmosphere, 
while BV173 (ACC 20, DSMZ) were maintained in RPMI 
20% FBS. Transient transfections were performed using 
Fugene HD transfection reagent (Roche Diagnostic S.p.A, 
Milan, Italy) according to the manufacturer’s instructions. 
To enrich the percentage of transfected cells, two days 
after the transfection stable clones were selected with 
G418 (100µg/ml) and then expanded to perform functional 
assays. For functional experiments 50 ng/ml Epidermal 
Growth Factor ligand (EGF; E9644, Sigma-Aldrich, St. 
Louis, MO) was added to the medium for different times 
points (0, 30 and 120 minutes) 24 hours post transfection. 
80µM of Rac inhibitor NSC23766 (Calbiochem, EMD 
Millipore Corporation, Billerica, MA, USA) was used for 
24 hours to inactivate Rac activity in HeLa cells. 
Antibodies used in western blotting, 
immunoprecipitation and immunofluorescence assay: 
western blot analysis were performed according to 
widely used protocols using antibodies directed against 
Bcr, Ciclin D , (Santa Cruz Biotecnology, Dallas, Texas, 
USA), OOF (α BCR/ABL-OOF) (rabbit polyclonal of 
our production), phosphorylated EGF receptor, total 
and phosphorylated Akt (Cell Signalling technology, 
Danvers, MA) total and phosphorylated p38 (Cell 
Signalling technology, Danvers, MA). Mouse monoclonal 
GM130 (BD Trasduction Laboratories, BD Biosciences, 
California, USA), Actin and GAPDH (Santa Cruz 
Biotecnology, Dallas, Texas, USA) antibodies were also 
used as loading control proteins (Santa Cruz Biotecnology, 
Dallas, Texas, USA).
Immunofluorescence assay was performed with 
Rac (EMD Millipore Corporation, Billerica, MA, USA), 
Rho (Santa Cruz Biotecnology, Dallas, Texas, USA), Bcr 
(Santa Cruz Biotecnology, Dallas, Texas, USA), EEA1 
and rabbit polyclonal anti-OOF.
Immunofluorescence assay
HeLa cells plated on glass coverslips were fixed in 
4% PFA for 10 min After cell permeabilization with 0,5% 
triton for 5 min, cells were blocked for 45 min with PBS 
10% BSA. Cells were then incubated for 2 hours with the 
specific primary antibody, and the immunocomplex was 
detected by 30 min incubation with secondary antibody 
(Alexa Fluor 488 or 543, Life Technologies Corporation). 
Phalloidin (Alexa Fluor 568, Life Technologies 
Corporation) was also used to analyse the cytoskeleton 
structure by incubation for 30 min after secondary 
antibody incubation. Cells were visualized under a Leica 
Gmbh fluorescence microscope using Qfluo software 
(Leica Microsystem) and confocal scanning microscope 
(LSM 5110; Carl Zeiss Microlmaging Inc., 63X 
objective). To analyze the vesicular compartment, before 
fixation cells were treated with a solution containing 
PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)), 0,1% 
Saponin.This solution lead to the formation of micro pores 
on the cell membrane. Under this experimental condition 
all cytoplasmatic components are eliminated and only the 
cytoskeleton and the organelle structure remain linked to 
the cell. 
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Cell lysis, immunoprecipitation and western blot 
assay
Total cell extraction was performed using TNE 
buffer (50 mM Tris pH 8,8, 2mM EDTA, 1% NP-40) 
supplemented with protease and phosphatise inhibitors 
(1 mM Na3VO4, 1 mM PMSF, 2µg/ml leupeptin, 2µg/
ml aprotinin, 2µg/ml pepstatin). Protein extracts 
were clarified by centrifugation at 12000g for 15 min 
at 4°C and subsequently quantified with Bio-Rad 
Protein Assay (BioRad laboratories, CA, USA). For 
immunoprecipitation experiments 500 µg proteins extracts 
were pre-cleared with agarose-conjugated normal IgG 
(SantaCruz Biotechnology, Dallas, Texas, USA) for 1 
hour at 4°C and then precipitated overnight with 1µg of 
the appropriate antibody along with protein A-agarose 
beads. The immunoprecipitate and protein samples were 
then resolved by SDS-PAGE and subsequently transferred 
onto nitrocellulose filter. 
Immunoblots were then probed overnight at 4°C 
with specific antibodies in PBS 0,1% tween, 1% BSA 
and protein detection was performed by using peroxidise-
conjugated secondary antibodies and chemiluminescent 
enhanced chemiluminescence reagent. 
Mixed microsomal fractions extraction
To isolate cytosol from microsomal fractions, and 
a mixture of different organelles (Golgi, endoplasmic 
reticulum and intracellular vesicles), a previously 
described protocol was used [23]. Briefly, the cells were 
resuspended into 250-STMDPS buffer (250mM sucrose, 
50mM Tris-Hcl (pH 7,4), 5mM MgCl2 , DTT 1mM, 
protease and phosphatase inhibitors), homogenized for 
2 min and subsequently centrifuged at 800g for 15 min. 
To obtain a cleaner preparation, the supernatant was 
centrifuged a second time and then collected for the 
isolation of mitochondria, cytosol and microsomes. To 
discard the mitochondria contamination, the supernatant 
collected was subjected to another centrifuged at 6,000g 
for 15 min. To separate the cytosol from microsomal 
fraction supernatant was centrifuged in a swing-bucket 
ultracentrifuge at 100,000g for 1hr. Once the supernatant 
was collected as pure cytosol, the remaining pellet was 
solubilised in ME buffer (20mM Tris-HCl (pH 7,8), 0,4M 
NaCl, 15% glycerol, 1mM DTT, 1,5% Triton-X-100, 
protease and phosphatase inhibitors) and centrifuged at 
9,000g for 30 min to extract microsomal proteins. Finally 
the different fractions were frozen for analysis at a later 
date by western blot using polyclonal anti OOF antibody 
and specific antibodies of cytosolic marker compartment 
(anti Actin, Santa Cruz Biotechnology) and microsomal 
(anti GM130, BD Transduction Laboratories, BD 
Biosciences).
GST Pulldown Assay to evaluate Rac activity: 
pGEX PAK-CD was expressed in TOP F10 cells by 
induction with isopropyl-L-thio-B-D-galactopyranoside 
(IPTG) 0,1mM according manufacturer’s instructions. 
Briefly, bacteria were pelleted, resuspended in lysis buffer 
and sonicated. After centrifugation, the clarified cell lysate 
containing the fusion protein GST-PAK was incubated 
with GST-fusion protein beads for 90 min at 4°C. The 
beads linked with GST-PAK were washed 4 times with 
PBS 0,5% triton to remove the unbound proteins and 
subsequently incubated for 1 hour with GST FISH buffer 
lysates (5% glycerol, 50mM Tris pH 7,4, 100mM NaCl, 
2mM MgCl2) from HeLa cells transfected with pCDNA 
3.1 BCR/ABL-OOF, pcDNA 3.1 RACV12 as positive 
control, respectively and empty pcDNA 3.1 as negative 
control. Beads-bound complexes were washed four times 
with FISH buffer and boiled in Laemmli sample buffer. 
The samples were fractionated in 15% SDS-PAGE and 
subsequently transferred to a nitrocellulose membrane for 
western blot analysis. 
Apoptosis assay
Apoptosis rate was analysed by flow cytometry 
analysis, using Annexin V Kit reagent (Immunostep 
Research). Cells transfected with empty pCDNA3.1 and 
pcDNA 3.1 BCR/ABL-OOF were detached and incubated 
with anti Annexin V antibody and red propidium for 
15 min, respectively. Cells were washed with PBS and 
then analysed by flow cytometry in order to quantify the 
apoptosis rate under different cells conditions.
Proliferation assay
Forty-eight hours after transfection, empty pCDNA 
3.1, pcDNA 3.1 BCR/ABL-OOF and pcDNA 3.1 BCR/ABL 
cells were starved for 12 hours and 1 μCi/ml of thymidine 
(GE Healthcare, Piscataway Township, NJ, USA) was 
added with or without 80 µM of Rac inhibitor NSC23766. 
Thymidine incorporation was evaluated after 24 hours; 
cells were washed 2 times with cold PBS and fixed with 
5% trichloroacetic (TCA) for 30 min, respectively. After 
washing, NaOH 1M was added for 20 min followed by 
adding HCl 2M to stop the reaction. The correct quantity 
of Thymidine incorporated was measured by a β-counter 
instrument.
Spreading assay
HeLa cells transfected with respective constructs 
were detached with PBS 5mM EDTA after overnight 
starvation and were plated on 10µg/ml fibronectin-coated 
glass coverslips (Marlenfeld GmbH&Co.KG, Germany) 
with RPMI without serum. The well plate was placed 
into an incubator at different time conditions and rapidly 
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fixed with 4% PFA. Immunofluorescence assay was then 
performed using the specific antibodies and phalloidin to 
stain actin filamentsstaining. 
Migration assay
Transwell filters were used (8µm pore size plate, 
Corning Incorporated, Corning, NY, USA) to analyse cell 
migration of transfected HeLa cells. Cells were detached 
from the cell plate with PBS 5mM EDTA and 1x104 cells 
were seeded in the upper layer of a transwell after an 
overnight starvation. The transwell membrane was coated 
with fibronectin 10mg/ml at 4°C overnight to facilitate the 
cell’s adherence. A specific stimulation (RPMI+FBS 20%) 
was placed below the cell permeable membrane. Cells 
were incubated for 22 hours at 37°C, 5% CO2 Transwell 
filters were washed three times with PBS and migrating 
cells were visualized and counted by May Grunwald 
Giemsa staining (Diapath, Martinengo, Italy).
Statistics
 Two-sided Student’s t test was calculated using 
GraphPad Prism software. P values < 0.05 were considered 
statistically significant. 
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